Caveolin-1 expression in benign and malignant lesions of the breast

World Journal of Surgical Oncology

Volumn 5, Issue , 2007, Pages

  Liedtke, Cornelia ^a   Kersting, Christian ^b   Bürger, Horst ^c   Kiesel, Ludwig ^a   Wülfing, Pia ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c Institute of Pathology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAVEOLIN 1; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST CARCINOMA; BREAST DISEASE; BREAST EPITHELIUM; BREAST FIBROADENOMA; BREAST HYPERPLASIA; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; DISEASE MARKER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MASTECTOMY; PAGET NIPPLE DISEASE; PATHOGENESIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SCAR FORMATION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY;

EID: 36448959111     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-5-110     Document Type: Article

References (33)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108. 15761078
2. Fielding CJ, FieldinS PE: Cholesterol and caveolae: structural and functional relationships. Biochim Biophys Acta 2000, 1529:210-22. 11111090
3. Li S, Okamoto T, Chun M, Sargiacomo M, Casanova JE, Hansen SH, Nishimoto I, Lisanti MP: Evidence for a regulated interaction between heterotrimeric G proteins and caveolin. J Biol Chem 1995, 270(26):15693-15701. 10.1074/jbc.270.26.15693 7797570
4. Song KS, Li S, Okamoto T, Quilliam LA, Sargiacomo M, Lisanti MP: Co-purification and direct interaction of Ras with caveolin, an integral membrane protein of caveolae microdomains. J Biol Chem 1996, 271:9690-7. 10.1074/jbc.271.16.9690 8621645
5. Garcia-Cardena G, Martasek P, Masters BS, Skidd PM, Couet J, Li S, Lisanti MP, Sessa WC: Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the nos caveolin binding domain in vivo. J Biol Chem 1997, 272:25437-40. 10.1074/ jbc.272.41.25437 9325253
6. Lisanti MP, Scherer PE, Tang Z, Sargiacomo M: Caveolae, caveolin and caveolin-rich membrane domains: A signalling hypothesis. Trends Cell Biol 1994, 4:231-5. 10.1016/0962-8924(94)90114-7 14731661
7. Koleske AJ, Baltimore D, Lisanti MP: Reduction of caveolin and caveolae in oncogenically transformed cells. Proc Natl Acad Sci USA 1995, 92:1381-5. 42523 7877987 10.1073/pnas.92.5.1381
8. Suzuoki M, Miyamoto M, Kato K, Hiraoka K, Oshikiri T, Nakakubo Y, Fukunaga A, Shichinohe T, Shinohara T, Itoh T, Kondo S, Katoh H: Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma. Br J Cancer 2002, 87:1140-4. 10.1038/sj.bjc.6600619 12402154
9. Yoo SH, Park YS, Kim HR, Sung SW, Kim JH, Shim YS, Lee SD, Choi YL, Kim MK, Chung DH: Expression of caveolin-1 is associated with poor prognosis of patients with squamous cell carcinoma of the lung. Lung Cancer 2003, 42:195-202. 10.1016/S0169-5002(03)00287-3 14568687
10. Campbell L, Gumbleton M, Griffiths DF: Caveolin-1 overexpression predicts poor disease-free survival of patients with clinically confined renal cell carcinoma. Br J Cancer 2003, 89:1909-13. 10.1038/ sj.bjc.6601359 14612902
11. Yang G, Truong LD, Wheeler TM, Thompson TC: Caveolin-1 expression in clinically confined human prostate cancer: A novel prognostic marker. Cancer Res 1999, 59:5719-23. 10582690
12. Engelman JA, Lee RJ, Karnezis A, Bearss DJ, Webster M, Siegel P, Muller WJ, Windle JJ, Pestell RG, Lisanti MP: Reciprocal regulation of neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Implications for human breast cancer. J Biol Chem 1998, 273:20448-55. 10.1074/jbc.273.32.20448 9685399
13. Zenklusen JC, Bieche I, Lidereau R, Conti CJ: (C-A)n microsatellite repeat D7S522 is the most commonly deleted region in human primary breast cancer. Proc Natl Acad Sci USA 1994, 91:12155-8. 45395 7991599 10.1073/pnas.91.25.12155
14. Hurlstone AF, Reid G, Reeves JR, Fraser J, Strathdee G, Rahilly M, Parkinson EK, Black DM: Analysis of the CAVEOLIN-1 gene at human chromosome 7q31.1 in primary tumours and tumour-derived cell lines. Oncogene 1999, 18:1881-90. 10.1038/sj.onc.1202491 10086342
15. Wulfing P, Diallo R, Kersting C, Wulfing C, Poremba C, Rody A, Greb RR, Bocker W, Kiesel L: Expression of endothelin-1, endothelin-A, and endothelin-B receptor in human breast cancer and correlation with long-term follow-up. Clin Cancer Res 2003, 9:4125-31. 14519635
16. Wulfing P, Diallo R, Muller C, Wulfing C, Poremba C, Heinecke A, Rody A, Greb RR, Bocker W, Kiesel L: Analysis of cyclooxygenase-2 expression in human breast cancer: High throughput tissue microarray analysis. J Cancer Res Clin Oncol 2003, 129:375-82. 10.1007/s00432-003-0459-1 12884024
17. Holland R, Peterse JL, Millis RR, Eusebi V, Faverly D, van de Vijver MJ, Zafrani B: Ductal caAcinoma in situ: A proposal for a new classification. Semin Diagn Pathol 1994, 11:167-80. 7831528
18. Wulfing P, Kersting C, Buerger H, Mattsson B, Mesters R, Gustmann C, Hinrichs B, Tio J, Bocker W, Kiesel L: Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ. Br J Cancer 2005, 92:1720-8. 10.1038/sj.bjc.6602567 15841074
19. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998, 4:844-7. 10.1038/nm0798-844 9662379
20. Sagara Y, Mimori K, Yoshinaga K, Tanaka F, Nishida K, Ohno S, Inoue H, Mori M: Clinical significance of Caveolin-1, Caveolin-2 and HER2/neu mRNA expression in human breast cancer. Br J Cancer 2004, 91:959-65. 15305200
21. Savage K, Lambros MB, Robertson D, Jones RL, Jones C, Mackay A, James M, Hornick JL, Pereira EM, Milanezi F, Fletcher CD, Schmitt FC, Ashworth A, Reis-Filho JS: Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: A morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res 2007, 13:90-101. 10.1158/1078-0432.CCR-06-1371 17200343
22. Glenney JR Jr, Tyrosine phosphorylation of a 22-kDa protein is correlated with transformation by Rous sarcoma virus. J Biol Chem 1989, 264:20163-6. 2479645
23. Yang G, Truong LD, Timme TL, Ren C, Wheeler TM, Park SH, Nasu Y, Bangma CH, Kattan MW, Scardino PT, Thompson TC: Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res 1998, 4:1873-80. 9717814
24. Pinilla SM, Honrado E, Hardisson D, Benitez J, Palacios J: Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. Breast Cancer Res Treat 2006, 99:85-90. 10.1007/s10549-006-9184-1 16541313
25. Kersting C, Packeisen J, Leidinger B, Brandt B, von Wasielewski R, Winkelmann W, van Diest PJ, Gosheger G, Buerger H: Pitfalls in immunohistochemical assessment of EGFR expression in soft tissue sarcomas. J Clin Pathol 2006, 59:585-90. 10.1136/jcp.2005.028373 16461571
26. Williams TM, Medina F, Badano I, Hazan RB, Hutchinson J, Muller WJ: Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J Biol Chem 2004, 279:51630-46. 10.1074/jbc.M409214200 15355971
27. Fiucci G, Ravid D, Reich R, Liscovitch M: Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene 2003, 21(15):2365-2375. 10.1038/ sj.onc.1205300
28. Salatino M, Beguelin W, Peters MG, Carnevale R, Proietti CJ, Galigniana MD: Progestin-induced caveolin-1 expression mediates breast cancer cell proliferation. Oncogene 2006, 25:7723-39. 10.1038/sj.onc.1209757 16799639
29. Van den Eynden GG, Van Laere SJ, Van der Auwera I, Merajver SD, Van Marck EA, van Dam P: Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer. Breast Cancer Res Treat 2006, 95:219-28. 10.1007/s10549-005-9002-1 16244790
30. Shatz M, Liscovitch M: Caveolin-1 and cancer multidrug resistance: coordinate regulation of pro-survival proteins? Leuk Res 2004, 28:907-8. 10.1016/j.leukres.2004.03.013 15234566
31. Marx J Caveolae: A once-elusive structure gets some respect. Science 2001, 294:1862-95. 10.1126/science.294.5548.1862 11729300
32. Pramudji C, Shimura S, Ebara S, Yang G, Wang J, Ren C, Yuan Y, Tahir SA, Timme TL, Thompson TC: In situ prostate cancer gene therapy using a novel adenoviral vector regulated by the caveolin-1 promoter. Clin Cancer Res 2001, 7:4272-9. 11751529
33. Boccadoro M, Morgan G, Cavenagh J: Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int 2005, 5:18. 1164423 15929791 10.1186/1475-2867-5-18